A recent study indicates that patients who discontinue popular GLP-1 drugs like Mounjaro or Wegovy can put back on lost weight at a significantly accelerated pace than those who halt conventional diet and exercise programs.
Findings released in a prominent medical journal shows that while obese individuals often shed about a fifth of their total mass while on the medication, the mass returns at an estimated rate of 0.8 kg per month once they quit.
"Users buying such medications should be informed of the risk of quick weight regain when the medication is stopped," cautioned lead investigator Dr. Susan Jebb.
Such speed of recovery implies a return to original weight within about 18 months.
Analyzing Treatments
The study, which examined 37 of trials involving over 9,000 of participants, compared the effects of these new drugs with conventional dieting.
Scientists note that people who shed pounds through lifestyle changes alone typically see a slower weight regain—around 0.1 kg a month—post-intervention.
Explaining the Rapid Rebound
Experts suggest the way of the drugs accounts for the heightened rebound.
The injections imitate a body's own chemical called glucagon-like peptide-1, which controls feelings of fullness.
"Sustained high doses of GLP-1 concentrations several times higher than normal may cause the system to produce less of its own natural hormone, and may also lessen responsiveness to its effects," said Dr. Adam Collins, a nutrition specialist.
"Stopping of this hormone supplement means hunger is unsuppressed, making binge eating a significant risk."
An Ongoing Issue?
Health authorities recommend the injections for individuals with obesity-related health risks, accompanied by prescribed diet and exercise modifications.
A number of clinicians contend that, given the significant potential of relapse, the treatment might need to be ongoing.
This view is reinforced by pharmaceutical companies, who say that the results "emphasize the persistent character of excess weight," comparing it to managing conditions like hypertension.
User Accounts
Users who have stopped the medication report a intense resurgence of appetite.
"I experienced a switch that goes on and I was suddenly starving," said one woman.
This difficulty is worsened if patients have not established lasting lifestyle or habit changes during therapy.
Growing Interest
Recent estimates indicate that a significant number of adults in the UK have used weight-loss jabs in the past year, with desire being substantial.
- Adoption is greater among women compared to males.
- The 40s and 50s demographic shows the highest usage rates.
- A large proportion obtain the medications through private healthcare rather than the NHS.
In conclusion, researchers emphasize that while the jabs are potent agents for shedding pounds, they are not a standalone cure and long-term success relies on ongoing lifestyle changes.
